After Hours Top Gainers $SDST $HCAI $YYAI $VCRE $SHFS
Mehr anzeigen$9.440
+0.289 (+3.06%)Zum Schluss
Loading chart…
- Hoch
- 9.740
- Eröffnung
- 9.570
- Volumengewichteter Durchschnittskurs
- 9.51
- Volumen
- 25.16K
- Marktkap.
- —
- Tief
- 9.340
- Umsatz
- 239.20K
- EV/EBITDA, TTM
- 0.00
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
KI-Analyse of Vicore Pharma Holding AB (VCRE)
KaufenVicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Vicore Pharma Holding AB (VCRE) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von .
VCRE FAQ – beantwortet von Alphio AI
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB. It operates in the Healthcare sector.
Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.
Community
Mehr ↗Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.